Back to Journals » Patient Preference and Adherence » Volume 13

Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations

Authors Tchobaniouk LV, McAllister EE, Bishop DL, Carpentier RM, Heins KR, Haight RJ, Bishop JR

Received 7 September 2019

Accepted for publication 3 December 2019

Published 12 February 2020 Volume 2019:13 Pages 2233—2241

DOI https://doi.org/10.2147/PPA.S192418

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Johnny Chen


Lesia V Tchobaniouk,1 Erin E McAllister,2 Danielle L Bishop,3 Rachel M Carpentier,4 Katharine R Heins,4 Robert J Haight,5 Jeffrey R Bishop6,7

1Department of Pharmacy, North Memorial Health Hospital, Robbinsdale, MN, USA; 2Department of Pharmacy, Clement J. Zablocki VA Medical Center, Milwaukee, WI, USA; 3Department of Pharmacy, M Health Fairview St. Joseph’s Hospital, St. Paul, MN, USA; 4Department of Pharmacy, Fairview Pharmacy Services, Minneapolis, MN, USA; 5Pharmacy Services, University of Minnesota Medical Center, Minneapolis, MN, USA; 6Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA; 7Department of Psychiatry, Medical School, University of Minnesota, Minneapolis, MN, USA

Correspondence: Jeffrey R Bishop
Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA
Email jrbishop@umn.edu

Abstract: Adherence to antipsychotic medications is a major challenge in schizophrenia. Long-acting injectable antipsychotics have been shown to offer advantages over oral formulations. A new extended release formulation of risperidone for subcutaneous injection was developed to address issues of non-adherence. The aim of this manuscript was to compare the new subcutaneous formulation to currently available formulations of injectable risperidone and paliperidone to determine whether the novel delivery by subcutaneous injection may provide substantial benefits. A literature search was conducted using PubMed, OVID, and Cochrane Library electronic databases to assess the advantages and disadvantages of long-acting formulations of risperidone. Potential advantages of risperidone for subcutaneous injection include a simplified dosing and ease of administration. Potential disadvantages include injection site pain and medication cost.

Keywords: adherence, long-acting injections, antipsychotic medications, RBP-7000, risperidone

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]